Floatz logo

PE 2I

REM Sleep Behavior Disorder

Universitaire Ziekenhuizen KU LeuvenSmall moleculePhase 1/2Active
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
95/ 100

Competitive context

12 Active assets in the REM Sleep Behavior Disorder cohort.

Asset / SponsorPhaseRating
IOFLUPANE
Weill Medical College of Cornell University
Phase 4BBB
.GAMMA.-HYDROXYBUTYRATE SODIUM SALT
Stanford University
Phase 4BB
Meta-Iodobenzylguanidine
Mayo Clinic
Phase 4BB
Clonazepam
Seoul National University Hospital
Phase 2B
Tvp-1012
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2/3B

View all 18 →

Same molecule, other indications

PE 2I is also rated in:

Parkinson diseaseDormant
CC
Indicative ·
44 / 100
View asset →
amyotrophic lateral sclerosisDormant
D
Indicative ·
30 / 100
View asset →
Alzheimer diseaseDormant
D
Indicative ·
30 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →